Literature DB >> 34250148

Soft tissue metastasis of the penis detected by copper-64 labeled prostate-specific membrane antigen positron emission tomography (64Cu-PSMA PET/CT) in a patient with prostate cancer.

Cherin Farhan1, Siroos Mirzaei1.   

Abstract

Prostate cancer is considered to be the most common solid cancer affecting men worldwide and leading to a significant morbidity and mortality. Metastases are usually seen in bone or lymph nodes. For recurrent disease, PET imaging with 68Ga-PSMA-11 (also known as HBED-CC, Glu-urea-Lys(Ahx)-HBED-CC, and PSMA-HBED-CC) is widely used. However, preparation of 68Ga-PSMA ligand requires the presence of radiochemistry facilities and can therefore not be utilized in centers lacking such facilities. Recently, copper labeled prostate-specific membrane antigen positron emission tomography (64Cu-PSMA PET/CT) demonstrated promising results in patients with recurrent disease and in the primary staging of selected patients with progressive local disease. In the present case, a rare manifestation site of a metastatic lesion in a patient with advanced prostate cancer is detected by 64Cu-PSMA PET/CT.
© 2021 mums.ac.ir All rights reserved.

Entities:  

Keywords:  64Cu-PSMA PET/CT; Penile metastasis; Prostate cancer

Year:  2021        PMID: 34250148      PMCID: PMC8255521          DOI: 10.22038/AOJNMB.2021.53922.1371

Source DB:  PubMed          Journal:  Asia Ocean J Nucl Med Biol        ISSN: 2322-5718


  9 in total

Review 1.  Tumour targeting with radiometals for diagnosis and therapy.

Authors:  Caterina F Ramogida; Chris Orvig
Journal:  Chem Commun (Camb)       Date:  2013-05-25       Impact factor: 6.222

2.  More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Authors:  Nikoletta K Pianou; Petros Z Stavrou; Evangelia Vlontzou; Phivi Rondogianni; Demetrios N Exarhos; Ioannis E Datseris
Journal:  Hell J Nucl Med       Date:  2019-03-07       Impact factor: 1.102

3.  64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy.

Authors:  Rodney J Hicks; Price Jackson; Grace Kong; Robert E Ware; Michael S Hofman; David A Pattison; Timothy A Akhurst; Elizabeth Drummond; Peter Roselt; Jason Callahan; Roger Price; Charmaine M Jeffery; Emily Hong; Wayne Noonan; Alan Herschtal; Lauren J Hicks; Amos Hedt; Matthew Harris; Brett M Paterson; Paul S Donnelly
Journal:  J Nucl Med       Date:  2018-11-15       Impact factor: 10.057

4.  Peptide and pseudo-peptide.

Authors:  Siroos Mirzaei; Rainer W Lipp
Journal:  Q J Nucl Med Mol Imaging       Date:  2020-10-12       Impact factor: 2.346

5.  Theranostics of Metastatic Prostate Cancer Applying 64Cu/18F/68Ga PSMA PET-CT and 177Lu Radiopharmaceuticals.

Authors:  Siroos Mirzaei; Fairoz Mohammed; Shahin Zandieh
Journal:  Curr Radiopharm       Date:  2021

Review 6.  Which metabolic imaging, besides bone scan with 99mTc-phosphonates, for detecting and evaluating bone metastases in prostatic cancer patients? An open discussion.

Authors:  E Bombardieri; L Setti; M Kirienko; L Antunovic; P Guglielmo; G Ciocia
Journal:  Q J Nucl Med Mol Imaging       Date:  2015-09-03       Impact factor: 2.346

7.  64Cu-PSMA-617 PET/CT Imaging of Prostate Adenocarcinoma: First In-Human Studies.

Authors:  Bernhard Grubmüller; Richard P Baum; Enza Capasso; Aviral Singh; Yasaman Ahmadi; Peter Knoll; Andreas Floth; Sergio Righi; Shahin Zandieh; Carlo Meleddu; Shahrokh F Shariat; Hans Christoph Klingler; Siroos Mirzaei
Journal:  Cancer Biother Radiopharm       Date:  2016-10-07       Impact factor: 3.099

8.  Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.

Authors:  Ali Afshar-Oromieh; Tim Holland-Letz; Frederik L Giesel; Clemens Kratochwil; Walter Mier; Sabine Haufe; Nils Debus; Matthias Eder; Michael Eisenhut; Martin Schäfer; Oliver Neels; Markus Hohenfellner; Klaus Kopka; Hans-Ulrich Kauczor; Jürgen Debus; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05-12       Impact factor: 9.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.